项目将精力分散到每个团队，却因处理38,000名归属生命的团队已满负荷运转，而使基于价值的合同下的每集成本保持不变。 对医疗服务提供商来说，这更难的原因是结构性的：已在38,000名生命上接受了下行风险，却缺乏定价所需每集成本数据。因此任何可信的答案都必须将每集成本和支付方组合置于同一视角，这正是大多数内部分析停滞之处，因为两者存在于不同系统中。
项目将精力分散到每个团队，却因处理38,000名归属生命的团队已满负荷运转，而使基于价值的合同下的每集成本保持不变。 对医疗服务提供商来说，这更难的原因是结构性的：已在38,000名生命上接受了下行风险，却缺乏定价所需每集成本数据。因此任何可信的答案都必须将每集成本和支付方组合置于同一视角，这正是大多数内部分析停滞之处，因为两者存在于不同系统中。
在任何时候，只有一个要素限制了从归属生命中获得的贡献，无论是一个提供者小组、一个审批步骤，还是高成本集的处理。该要素之外的活动只会增加未处理案例或文档量，而不会提升合同收入。项目来自有空闲时间的群体，因此满负荷的提供者或成本数据缺口从未成为焦点。
结果是可衡量的活动却让支付方组合和合同表现保持不变。标准工作和可见看板出现在不触及集成本的领域，而每提供者的贡献保持不变。后续项目则继续消耗本非限制环节的群体时间。
决定每提供者贡献的步骤往往包含错误案例，因为支付方组合和集选择未被审查。在那里优化方法只会降低继续侵蚀合同利润的工作成本。
效率转型策略（目录编号T12）从决定归属生命每集成本和每提供者贡献的要素入手，然后说明必须改变什么才能让新增产能改善合同结果。如果限制确实是流程速度，则精益项目从该诊断出发，且仅针对已识别点。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 已完成项目不断积累，而每集成本和基于价值合同的利润率却无变化。
✓ 医务主任和CFO指认不同步骤为控制小组经济或集成本的关键。
✓ 吞吐量或文档的最大报告增益出现在已有可用提供者或员工时间的团队。
通常会让情况更糟的做法。 将标准方法推广到每个团队，把稀缺的项目产能耗在从未决定每集成本或每提供者贡献的步骤上。
It is for you if you run or finance a healthcare provider and a large number of completed improvement initiatives and unchanged output. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 效率转型策略, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
它们解决不同问题，选择哪种不如目标重要。精益针对流程和等待；六西格玛针对变异和缺陷。如果问题是事项排队，选精益。如果是输出不一致，选六西格玛。如果尚不清楚问题所在，方法选择为时过早，任何一种都会产生活动。
评估阶段大约花费£40k–£120k。完整部署并嵌入实践者和培训通常在一年内花费£250k–£1m，通常按承诺的节省倍数报价。请询问基线如何设定以及由谁验证节省，因为自行验证的效益是常态且系统性偏高。
方法可以——材料公开且廉价，许多公司已自学。真正难以自供的是外部判断：瞄准何处，以及愿意指出受青睐的部门并非问题所在。这才是值得购买的部分，且远小于一次完整部署。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית